Shanghai Hile Bio-Technology (603718.SH) suffered a 1% reduction in shareholding by shareholder Fangdeji, a well-known institutional investor, which is a concerted actor with well-known institutional investor Zhang Jianping.

Shanghai Hile Bio-Technology (603718.SH) announced that on September 24, 2024, the company received a notice from one of its shareholders, Fang Deji, who holds more than 5% of the total shares, regarding a change in equity reaching 1%. It was learned that from September 19, 2024 to September 24, 2024, Fang Deji reduced the company's unrestricted circulating shares by 6.5826 million shares through centralized auction trading, reaching 1% of the total share capital of the company. It is reported that Zhang Jianping, Fang Wenyan, Fang Zhangle, and Fang Deji, as concerted parties holding more than 5% of the company's shares, are the major shareholders. The equity change this time is due to Fang Deji, one of the shareholders, reducing the company's shares through centralized auction trading. After this equity change, Fang Deji's holding of the company's shares decreased from 3.18% to 2.18%, and the total percentage of shares held by Zhang Jianping, Fang Wenyan, Fang Zhangle, and Fang Deji decreased from 16.63% to 15.63%.